The impact of variant CJD on transfusion practices in the UK

Hobsbaum, 1995

Loefler, 2002, The contest between a clever virus and a facultatively clever host, J. Roy. Soc. Med, 95, 516, 10.1258/jrsm.95.10.516

Prusiner, 1998, Prions, 262

Jackson, 2001, Location and properties of metal-binding sites on the human prion protein, Proc Nat Acad Sci USA, 98, 8531, 10.1073/pnas.151038498

Phillips Report on the BSE Enquiry. TSO 2000 (see also http://www.bse.org.uk/)

BBC Radio 4 ‘Today Programme’, October 10, 2002

http://www.defra.gov.uk/animalh/bse/bse-publications/enforce/bseeb60.pdf

ourworld.cs.com/j1braakman/BSE1.htm

Lamar, 2001, Japan to test 1 m cattle after discovery of first case of BSE, Br. Med. J., 323, 713, 10.1136/bmj.323.7315.713b

Will, 1996, A new variant of Creutzfeldt–Jakob disease in the UK, Lancet, 347, 921, 10.1016/S0140-6736(96)91412-9

Spencer, 2002, First hundred cases of variant Creutzfeldt–Jakob disease: retrospective case note review of early psychiatric and neurological features, Br. Med. J., 324, 1479, 10.1136/bmj.324.7352.1479

Kaeser, 2001, Efficient lymphoreticular prion propagation requires PrPc in stromal and hematopoietic cells, J. Virol., 75, 7097, 10.1128/JVI.75.15.7097-7106.2001

Hilton, 2002, Accumulation of prion protein in tonsil and appendix: review of tissue samples, Br. Med. J., 325, 633, 10.1136/bmj.325.7365.633

Monk P, Bryant G. Final report of the investigation into the North Leicestershire cluster of variant Creutzfeldt–Jakob disease. Leicestershire Health Authority, 2001. www.leics-ha.org.uk/

Lee, 1998, Complete genomic sequence of three mammalian PrP genes, Genome Res., 1022, 10.1101/gr.8.10.1022

Jackson, 2001, HLA-DQ7antigen and resistance to variant CJD, Nature, 414, 269, 10.1038/35104694

Dealler, 2002, Possibility of BSE being cause of variant CJD is indeed biologically plausible, Br. Med. J., 325, 103

MacGregor, 2001, Prion protein and developments in its detection, Transfus. Med., 11, 3, 10.1046/j.1365-3148.2001.00285.x

Clewley, 2002, Any tests for vCJD yet?, Communicable Dis. Public Health, 5, 168

Anstee, 2002, Progress towards a blood test for vCJD?, Vox Sang, 83, 203, 10.1111/j.1423-0410.2002.tb05302.x

Prowse, 2002, Mad cows and Englishmen: an update on blood and vCJD, Vox Sang, 83, 341, 10.1111/j.1423-0410.2002.tb05331.x

Josefson, 2001, Drugs for malaria and psychosis may offer hope to people with CJD, Br Med J, 323, 416, 10.1136/bmj.323.7310.416b

Priola, 2002, Novel therapeutic uses for porphyrins and phthalcyanines in the transmissable spongiform encephalopathies, Curr. Opin. Microbiol., 2, 563, 10.1016/S1369-5274(99)00020-X

Love, 2001, Old drugs to treat new variant Creutzfeldt–Jakob disease, Lancet, 358, 563, 10.1016/S0140-6736(01)05748-8

Braunholtz, 2002, Quinacrine in possible or probable CJD: if you had suspected CJD would you be indifferent between placebo and quinacrine?, Br. Med. J., 324, 239, 10.1136/bmj.324.7331.239

Korth, 2001, Acridine and phenothiazine derivatives as pharmaco-therapeutics for prion disease, Proc. Nat. Acad. Sci. USA, 98, 9836, 10.1073/pnas.161274798

Prowse, 2002, SNBTS’ approaches to address the potential risk of vCJD in the blood supply, Transfus. Med., 12, 47

Dealler, 1998, Post exposure prophylaxis after accidental prion inoculation, Lancet, 351, 600, 10.1016/S0140-6736(05)78591-3

Aguzzi, 1997, Post-exposure prophylaxis after accidental prion inoculation, Lancet, 350, 1519, 10.1016/S0140-6736(05)63941-4

Lee, 2000, Monitoring plasma processing steps with a sensitive Western Blot assay for the detection of prion protein, J. Virol. Meth., 84, 77, 10.1016/S0166-0934(99)00135-4

MacGregor, 2002, Clearance of a BSE-derived agent by processes used in the manufacture of human immunoglobulin, Vox Sang, 83, 163

Hunter, 2002, Transmission of prion diseases by blood transfusion, J. Gen. Virol., 83, 2897, 10.1099/0022-1317-83-11-2897

Det Norske Veritas. Assessment of the risk of exposure to vCJD Infectivity in Blood and blood products, for the Spongiform Encephalopathy Advisory Committee and the Department of Health. February 1999

Baxter, 1998, New-variant Creutzfeldt–Jakob disease and treatment of haemophilia, Lancet, 1351, 600, 10.1016/S0140-6736(05)78593-7

MacGregor, 1999, Application of a time-resolved fluoroimmunoassay for the analysis of normal prion protein in human blood and its constituents, Vox Sang, 77, 88, 10.1046/j.1423-0410.1999.7720088.x

1994

McGill, 2002, Mechanical methods of reducing blood transfusion in cardiac surgery: randomised controlled trial, Br. Med. J., 324, 1299, 10.1136/bmj.324.7349.1299

UK Departments of Health. Health Circular 2002/009. Better Blood Transfusion. TSO;2002